MedTrace Logo

Evaluation of NM26-2198 in Healthy Subjects and in Patients With Moderate-to-severe Atopic Dermatitis (AD)

NCT05859724 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 126

Last updated 2026-04-13

No results posted yet for this study

Summary

This is a randomized, double-blind, placebo-controlled, single- and multiple ascending dose study of subcutaneous (SC) administration of NM26-2198 in healthy volunteers and adult patients with moderate to-severe AD to evaluate the safety, tolerability, pharmacokinetics (PK), and immunogenicity of single (SAD) and multiple doses (MAD) of NM26-2198.

Conditions

Interventions

BIOLOGICAL

NM26-2198

IL-4R/IL-31 bispecific antibody for subcutaneous administration

OTHER

Placebo

Placebo for NM26-2198

Sponsors & Collaborators

  • Yellow Jersey Therapeutics AG

    lead INDUSTRY

Principal Investigators

  • Yellow Jersey Therapeutics AG Clinical trial · Yellow Jersey Therapeutics AG

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-05-10
Primary Completion
2024-10-01
Completion
2024-10-17
FDA Drug
Yes

Countries

  • United States
  • Canada
  • Germany
  • Poland

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05859724 on ClinicalTrials.gov